0001493152-16-015109.txt : 20161216 0001493152-16-015109.hdr.sgml : 20161216 20161115152852 ACCESSION NUMBER: 0001493152-16-015109 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20161115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Akers Biosciences Inc CENTRAL INDEX KEY: 0001321834 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 201 GROVE RD CITY: THOROFARE STATE: NJ ZIP: 08086 BUSINESS PHONE: 856-848-8698 MAIL ADDRESS: STREET 1: 201 GROVE RD CITY: THOROFARE STATE: NJ ZIP: 08086 CORRESP 1 filename1.htm

AKERS BIOSCIENCES, INC.

201 GROVE ROAD

THOROFARE, NJ 08086

November 15, 2016

VIA EDGAR

U.S. Securities & Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

	Re:	Akers Biosciences, Inc.
		Registration Statement on Form S-3
		File No. 333-214214

Ladies and Gentlemen:

In accordance with Rule 461 of the Securities Act of 1933, as amended, Akers Biosciences, Inc. (the “Company”) hereby respectfully requests that the effective date of the above-captioned Registration Statement (the “Filing”) be accelerated so that it will be declared effective at 9:00 a.m. Eastern Time on Wednesday, November 16, 2016, or as soon thereafter as possible.

* * * *

Very Truly Yours,

Akers Biosciences, Inc.

/s/ John Gormally
John Gormally
Chief Executive Officer